Best of ASCO - 2014 Annual Meeting

 

Welcome

Vaccines

Developmental Therapeutics—Immunotherapy

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I study of multi-HLA-binding HSP70 + GPC3 peptides and combination adjuvants of LAG3-Ig + Poly-ICLC against gastrointestinal cancers.

Shoichi Hazama

e15167

An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.

Ramaswamy Govindan

TPS3134

Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia.

Rahul Ravilla

3099

First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.

Mikiya Ishihara

e15176

First-in-man study of Ad-sig-hMUC1/ecdCD40L vaccine for immunotherapy of MUC1 overexpressing epithelial cancers.

Tira Jing Ying Tan

3098

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.

Luigi Buonaguro

TPS3135

Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer.

Luke T. Nordquist

e15166

Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

Craig L. Slingluff

e15175

Phase I/II study of BSK01, an artificial intelligence-driven, peptide-pulsed, mature DC immunotherapy for solid and hematological malignancies.

Leonardo Mirandola

TPS3136

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.

Sapna Pradyuman Patel

e15171

SV-BR-1-GM a whole-cell targeted immunotherapy for breast cancer: Preliminary clinical data.

Jarrod P. Holmes

e15165

The effect of Newcastle disease virus on tumor proliferation and cellular immunity.

Anastasia O. Sitkovskaya

e15174

Utility of comprehensive genomic profiling (CGP) for personal cancer vaccine development via neoantigen analysis.

Dana Vuzman

3100

VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.

Irina Redchenko

3018